Arrhythmogenic Right Ventricular Cardiomyopathy: Difference between revisions

Jump to navigation Jump to search
Line 141: Line 141:
| colspan="2" style="padding-left:12px" | Major
| colspan="2" style="padding-left:12px" | Major
|-
|-
|
| style="padding-left:24px" |
* Epsilon waves or localized prolongation (&gt;110 ms) of the QRS complex in right precordial leads (V<sub>1</sub> to V<sub>3</sub>)
* Epsilon waves or localized prolongation (&gt;110 ms) of the QRS complex in right precordial leads (V<sub>1</sub> to V<sub>3</sub>)
|
|
Line 148: Line 148:
| colspan="2" style="padding-left:12px" | Minor
| colspan="2" style="padding-left:12px" | Minor
|-
|-
|
| style="padding-left:24px" valign="top" |
* Late potentials (SAECG)
* Late potentials (SAECG)
|
|
Line 167: Line 167:
| colspan="2" style="padding-left:12px" | Minor
| colspan="2" style="padding-left:12px" | Minor
|-
|-
|  
| style="padding-left:24px" valign="top" |
* Left bundle-branch block–type ventricular tachycardia (sustained and nonsustained) (ECG, Holter, exercise)
* Left bundle-branch block–type ventricular tachycardia (sustained and nonsustained) (ECG, Holter, exercise)
* Frequent ventricular extrasystoles (&gt;1000 per 24 hours) (Holter)
* Frequent ventricular extrasystoles (&gt;1000 per 24 hours) (Holter)
Line 173: Line 173:
* Nonsustained or sustained ventricular tachycardia of RV outflow configuration, left bundle-branch block morphology with inferior axis (positive QRS in leads II, III, and aVF and negative in lead aVL) or of unknown axis
* Nonsustained or sustained ventricular tachycardia of RV outflow configuration, left bundle-branch block morphology with inferior axis (positive QRS in leads II, III, and aVF and negative in lead aVL) or of unknown axis
* &gt;500 ventricular extrasystoles per 24 hours (Holter)
* &gt;500 ventricular extrasystoles per 24 hours (Holter)
 
|-
| colspan="2" | VI. Family history
|-
| colspan="2" style="padding-left:12px" | Major
|-
| style="padding-left:24px" valign="top" |
* Familial disease confirmed at necropsy or surgery
|
* ARVC/D confirmed in a first-degree relative who meets current Task Force criteria
* ARVC/D confirmed pathologically at autopsy or surgery in a first-degree relative
* Identification of a pathogenic mutation<sup>&dagger;</sup> categorized as associated or probably associated with ARVC/D in the patient under evaluation
|-
| colspan="2" style="padding-left:12px" | Minor
|-
| style="padding-left:24px" valign="top" |
* Family history of premature sudden death (&lt;35 years of age) due to suspected ARVC/D
* Familial history (clinical diagnosis based on present criteria)
|
* History of ARVC/D in a first-degree relative in whom it is not possible or practical to determine whether the family member meets current Task Force criteria
* Premature sudden death (&lt;35 years of age) due to suspected ARVC/D in a first-degree relative
* ARVC/D confirmed pathologically or by current Task Force Criteria in second-degree relative
|-
| colspan="2" |
<ul>
<li>PLAX indicates parasternal long-axis view; RVOT, RV outflow tract; BSA, body surface area; PSAX, parasternal short-axis view; aVF, augmented voltage unipolar left foot lead; and aVL, augmented voltage unipolar left arm lead.</li>
<li>Diagnostic terminology for original criteria: This diagnosis is fulfilled by the presence of 2 major, or 1 major plus 2 minor criteria or 4 minor criteria from different groups. Diagnostic terminology for revised criteria: definite diagnosis: 2 major or 1 major and 2 minor criteria or 4 minor from different categories; borderline: 1 major and 1 minor or 3 minor criteria from different categories; possible: 1 major or 2 minor criteria from different categories.</li>
<li><sup>&lowast;</sup> Hypokinesis is not included in this or subsequent definitions of RV regional wall motion abnormalities for the proposed modified criteria.</li>
<li><sup>&dagger;</sup> A pathogenic mutation is a DNA alteration associated with ARVC/D that alters or is expected to alter the encoded protein, is unobserved or rare in a large non–ARVC/D control population, and either alters or is predicted to alter the structure or function of the protein or has demonstrated linkage to the disease phenotype in a conclusive pedigree.</li>
</ul>
|}
|}


Navigation menu